Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023
DOI: 10.1002/phar.2759 ↗At a glance
Beobachtungsstudie in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Written by Bianca Aprilliano and 3 co-authors. Institution: Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA. Major MEDLINE topics: Venous Thromboembolism, Acute Kidney Injury. 19 references.
Abstract (original language)
Study Objective To compare bleeding and thromboembolic events in patients receiving therapeutic doses of apixaban or rivaroxaban versus unfractionated heparin (UFH) in patients with acute kidney injury (AKI).
Design
Single‐center, retrospective, observational study.
Setting
Ascension St. John Hospital in Detroit, Michigan. Patients Hospitalized adult patients who received therapeutic doses of factor Xa inhibitors ( n = 250) or UFH ( n = 250) for at least 24 h in the setting of AKI. Measurements and Main Results After adjusting for confounding factors, patients who received a factor Xa inhibitor experienced a lower risk of composite major and clinically relevant nonmajor bleeding (CRNMB) events compared with UFH (OR: 0.57, 95% CI: 0.34–0.94; p = 0.03). There was a significantly decreased risk of CRNMB events in the factor Xa inhibitor group (OR: 0.55, 95% CI: 0.33–0.91, p = 0.02); however, no significant differences in major bleeding or venous thromboembolism (VTE) were noted.
Conclusions
Our results suggest that it may be preferable to continue patients in AKI on factor Xa inhibitors versus transitioning to UFH due to the lower risk of bleeding events.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA.
- Department of Pharmacy, Wayne State University Eugene Applebaum Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, USA.
ORCID profiles: Stephanie B Edwin
Cite
APA
Aprilliano, B., Giuliano, C., Paxton, R. A., & Edwin, S. B. (2023). Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2759
Vancouver
Aprilliano B, Giuliano C, Paxton RA, Edwin SB. Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2759
BibTeX
@article{Aprilliano2023,
author = {Aprilliano, Bianca and Giuliano, Christopher and Paxton, Renee Alexander and Edwin, Stephanie B},
title = {Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
doi = {10.1002/phar.2759}
}
EUVIMED